Curcumin: a Polyphenol with Molecular Targets for Cancer Control

  • Published : 2016.06.01


Curcumin, is a polyphenol from Curcuma longa (turmeric plant), is a polyphenol that belongs to the ginger family which has long been used in Ayurveda medicines to treat various diseases such as asthma, anorexia, coughing, hepatic diseases, diabetes, heart diseases, wound healing and Alzheimer's. Various studies have shown that curcumin has anti-infectious, anti-inflammatory, anti-oxidant, hepatoprotective, thrombosuppressive, cardio protective, anti-arthritic, chemo preventive and anti-carcinogenic activities. It may suppress both initiation and progression stages of cancer. Anticancer activity of curcumin is due to negative regulation of inflammatory cytokines, transcription factors, protein kinases, reactive oxygen species (ROS) and oncogenes. This review focuses on the different targets of curcumin to treat cancer.


  1. Azmi L, Ojha SK, Rao CV (2015). Curcumin: boon for human beings. World J Pharmacy Pharmaceutical Sci, 4, 239-249.
  2. Bimonte S, Barbieri A, Palma G, et al (2015). Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. BioMed Res Int, 2015.
  3. Chaturvedi M, Sung B, Yadav V, Kannappan R, Aggarwal B (2011). NF-${\kappa}B$ addiction and its role in cancer:'one size does not fit all'. Oncogene, 30, 1615-30.
  4. Chen A, Xu J, Johnson A (2006). Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene, 25, 278-87.
  5. Chung M-Y, Lim TG, Lee KW (2013). Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development. World J Gastroenterol, 19, 984.
  6. Cildir G, Akincilar SC, Tergaonkar V (2013). Chronic adipose tissue inflammation: all immune cells on the stage. Trends Molecular Med, 19, 487-500.
  7. Das L and Vinayak M (2015). Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 Signalling and Modulation of Inflammation in Prevention of Cancer.
  8. Devassy JG, Nwachukwu ID, Jones PJ (2015). Curcumin and cancer: barriers to obtaining a health claim. Nutrition Rev, 64
  9. Divya CS, Pillai MR (2006). Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Molecular carcinogenesis, 45, 320-32.
  10. Donipati P, Sreeramulu SH (2015). In vitro anticancer activity of Curcuma longa against human breast cancer. Cell Line Mcf, 7.
  11. Ferreira L, Arbab A, Jardim-Perassi B, et al (2015a). Effect of curcumin on pro-angiogenic factors in the xenograft model of breast cancer. Anticancer Agents Med Chem, 15, 1285-96.
  12. Ferreira LC, Arbab AS, Jardim-Perassi BV, (2015b). Abstract A02: Effect of curcumin on the tumor growth and angiogenesis of breast cancer. Cancer Res, 75, A02-A02.
  13. Fiala M (2015). Curcumin and omega-3 fatty acids enhance NK cell-induced apoptosis of pancreatic cancer cells but curcumin inhibits interferon-${\gamma}$ production: benefits of omega-3 with curcumin against cancer. Molecules, 20, 3020-6.
  14. Gao W, Chan JY, Wei WI, Wong TS (2012). Anti-cancer effects of curcumin on head and neck cancers. Anticancer Agents Med Chem, 12, 1110-6.
  15. Gee VM, Wong FS, Ramachandran L, et al (2014). Identification of novel peroxisome proliferator-activated receptor-gamma ($PPAR{\gamma}$). agonists using molecular modeling method. J Computer-Aided Molecular Design, 28, 1143-51.
  16. Gupta SC, Patchva S, Aggarwal BB (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 15, 195-218.
  17. Gupta SC, Prasad S, Kim JH, et al (2011). Multitargeting by curcumin as revealed by molecular interaction studies. Natural Product Reports, 28, 1937-55.
  18. Huang T, Chen Z, Fang L (2013). Curcumin inhibits LPS-induced EMT through downregulation of NF-${\kappa}B$-Snail signaling in breast cancer cells. Oncol Reports, 29, 117-124.
  19. Kapakos G, Youreva V, Srivastava AK (2012). Attenuation of endothelin-1-induced PKB and ERK1/2 signaling, as well as Egr-1 expression, by curcumin in A-10 vascular smooth muscle cells. Canadian J Physiol Pharmacol, 90, 1277-85.
  20. Kolch W, Pitt A (2010). Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nature Reviews Cancer, 10, 618-29.
  21. Lemmon MA, Schlessinger J (2010). Cell signaling by receptor tyrosine kinases. Cell, 141, 1117-34.
  22. Li F, Sethi G (2010). Targeting transcription factor NF-${\kappa}B$ to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta -Reviews on Cancer, 1805, 167-80.
  23. Li X, Chen S, Zhang B, et al (2012). In situ injectable nano-composite hydrogel composed of curcumin, N, O-carboxymethyl chitosan and oxidized alginate for wound healing application. Int J Pharmaceutics, 437, 110-9.
  24. Lopez-Bergami P, Lau E, Ronai Ze (2010). Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nature Review Cancer, 10, 65-76.
  25. Low KC , Tergaonkar V (2013). Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochemical Sciences, 38, 426-34.
  26. Mishra A, Kumar R, Tyagi A, et al (2015). Curcumin modulates cellular AP-1, NF-kB, and HPV16 E6 proteins in oral cancer. Ecancermedicalscience, 9.
  27. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE (2014). Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials, 35, 3365-83.
  28. Niu T, Tian Y, Cai Q, Ren Q, Wei L (2015). Red light combined with blue light irradiation regulates proliferation and apoptosis in skin keratinocytes in combination with low concentrations of curcumin. PloS One, 10, 138754.
  29. Norris L, Karmokar A, Howells L, et al (2013). The role of cancer stem cells in the anti-carcinogenicity of curcumin. Mol Nutr Food Res, 57, 1630-7.
  30. Nunez-Sanchez MA, , Romo-Vaquero M, et al (2015). Dietary phenolics against colorectal cancer-From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs. Mol Nutr Food Res, 59, 1274-91.
  31. Park W, Amin AR, Chen ZG, Shin DM (2013). New perspectives of curcumin in cancer prevention. Cancer Prev Res, 6, 387-400.
  32. Roux PP, Blenis J (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Molecular Biol Reviews, 68, 320-44.
  33. Sareen R, Jain N, Pandit V (2013). Curcumin: A boon to colonic diseases. Current Drug Targets, 14, 1210-8.
  34. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V (2012). Multifaceted link between cancer and inflammation. Bioscience Reports, 32, 1-15.
  35. Sethi G, Sung B, Aggarwal BB (2008). Nuclear factor-${\kappa}B$ activation: from bench to bedside. Exp Biol Med, 233, 21-31.
  36. Sethi G, Tergaonkar V (2009). Potential pharmacological control of the NF-${\kappa}B$ pathway. Trends Pharmacological Sci, 30, 313-21.
  37. Shanmugam MK, Kannaiyan R, Sethi G (2011). Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer, 63, 161-73.
  38. Shanmugam MK, Rane G, Kanchi MM, et al (2015). The multifaceted role of curcumin in cancer prevention and treatment. Molecules, 20, 2728-69.
  39. Shanmugam MK, Sethi G (2013). Role of epigenetics in inflammation-associated diseases. Subcell Biochem, 61, 627-57.
  40. Sharma S, Kulkarni SK, Chopra K (2006). Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 33, 940-5.
  41. Shehzad A, Lee J, Lee YS (2013). Curcumin in various cancers. Biofactors, 39, 56-68.
  42. Siveen KS, Sikka S, Surana R, et al (2014). Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta - Reviews on Cancer, 1845, 136-54.
  43. Soetikno V, Sari FR, Sukumaran V, et al (2013). Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats. J Nutritional Biochem, 24, 796-802.
  44. Subramaniam A, Shanmugam MK, Perumal E, et al (2013). Potential role of signal transducer and activator of transcription (STAT). 3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta -Reviews on Cancer, 1835, 46-60.
  45. Tyagi AK, Prasad S (2015). Targeting P53 Pathway by curcumin for cancer prevention and treatment. Cell Dev Biol, 4, 2.
  46. Wu J, Tang Q, Zhao S, et al (2014). Extracellular signalregulated kinase signaling-mediated induction and interaction of FOXO3a and p53 contribute to the inhibition of nasopharyngeal carcinoma cell growth by curcumin. Int J Oncol, 45, 95-103.
  47. Xi Y, Gao H, Callaghan MU, et al (2015). Induction of BCL2-interacting killer, BIK, is mediated for anti-cancer activity of curcumin in human head and neck squamous cell carcinoma cells. J Cancer, 6, 327.
  48. Yallapu MM, Nagesh PKB, Jaggi M, Chauhan SC (2015). Therapeutic applications of curcumin nanoformulations. AAPS J 17, 1341-56.
  49. Yao Q, Lin M, Wang Y, et al (2015). Curcumin induces the apoptosis of A549 cells via oxidative stress and MAPK signaling pathways. Int J Molecular Med, 36, 1118-26.
  50. Zlotogorski A, Dayan A, Dayan D, et al (2013). Nutraceuticals as new treatment approaches for oral cancer-I: curcumin. Oral Oncol, 49, 187-191.
  51. Zong H, Wang F, Fan Q-X, Wang L-X (2012). Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NFkappa B signaling pathways. Molecular Biology Reports, 39, 4803-8.